Edap Tms Sa (EDAP) Upgraded at Zacks Investment Research
Edap Tms Sa (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The firm currently has a $3.25 price objective on the stock. Zacks Investment Research’s target price suggests a potential upside of 14.04% from the stock’s previous close.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
EDAP has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating on shares of Edap Tms Sa in a report on Tuesday, August 30th. TheStreet raised shares of Edap Tms Sa from a “sell” rating to a “hold” rating in a report on Tuesday, September 27th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/edap-tms-sa-edap-upgraded-at-zacks-investment-research.html
Edap Tms Sa (NASDAQ:EDAP) traded up 4.78% during mid-day trading on Tuesday, hitting $2.85. 112,415 shares of the stock traded hands. Edap Tms Sa has a 52 week low of $2.43 and a 52 week high of $6.57. The firm’s 50-day moving average price is $2.92 and its 200-day moving average price is $3.26. The firm has a market cap of $81.87 million, a P/E ratio of 17.38 and a beta of 1.12.
Edap Tms Sa (NASDAQ:EDAP) last released its quarterly earnings data on Thursday, August 25th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.12. Edap Tms Sa had a net margin of 11.53% and a return on equity of 58.61%. On average, equities analysts forecast that Edap Tms Sa will post $0.16 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Edap Tms Sa stock. Perkins Capital Management Inc. acquired a new position in shares of Edap Tms Sa (NASDAQ:EDAP) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 118,000 shares of the company’s stock, valued at approximately $391,000. Perkins Capital Management Inc. owned approximately 0.46% of Edap Tms Sa at the end of the most recent reporting period. 12.11% of the stock is owned by institutional investors and hedge funds.
Edap Tms Sa Company Profile
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Sa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms Sa and related companies with MarketBeat.com's FREE daily email newsletter.